Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Accounts Payables (2022 - 2025)

Mangoceuticals' Accounts Payables history spans 4 years, with the latest figure at $416682.0 for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 50.25% to $416682.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $416682.0, a 50.25% decrease, with the full-year FY2025 number at $416682.0, down 50.25% from a year prior.
  • Accounts Payables hit $416682.0 in Q4 2025 for Mangoceuticals, down from $526964.0 in the prior quarter.
  • Over the last five years, Accounts Payables for MGRX hit a ceiling of $1.2 million in Q1 2025 and a floor of $30796.0 in Q1 2023.
  • Historically, Accounts Payables has averaged $507225.9 across 4 years, with a median of $526964.0 in 2025.
  • Biggest five-year swings in Accounts Payables: soared 3198.95% in 2024 and later plummeted 50.25% in 2025.
  • Tracing MGRX's Accounts Payables over 4 years: stood at $33675.0 in 2022, then skyrocketed by 318.01% to $140765.0 in 2023, then surged by 494.96% to $837501.0 in 2024, then crashed by 50.25% to $416682.0 in 2025.
  • Business Quant data shows Accounts Payables for MGRX at $416682.0 in Q4 2025, $526964.0 in Q3 2025, and $767996.0 in Q2 2025.